Vascular Calcification in CKD-MBD: Roles for Phosphate, FGF23, and Klotho

Overview

Journal Bone

Specialties Endocrinology
Orthopedics

Date 2016 Nov 17

PMID 27847254

Citations 159

Authors

Shunsuke Yamada

Cecilia M Giachelli

Affiliations

Soon will be listed here.

Abstract

Vascular calcification (VC) is highly prevalent in aging, diabetes mellitus, and chronic kidney disease (CKD). VC is a strong predictor of cardiovascular morbidity and mortality in the CKD population. Complex pathological mechanisms are involved in the development of VC, including osteochondrogenic differentiation and apoptosis of vascular smooth muscle cells, instability and release of extracellular vesicles loaded calcium and phosphate, and elastin degradation. Elevated serum phosphate is a late manifestation of CKD, and has been shown to accelerate mineral deposition in both the vessel wall and heart valves. α-Klotho and fibroblast growth factor 23 (FGF23) are emerging factors in CKD-mineral and bone disorder (CKD-MBD) and are thought to be involved in the pathogenesis of uremic VC. There are discordant reports regarding the biomedical effects of FGF23 on VC. In contrast, mounting evidence supports a well-supported protective role for α-Klotho on VC. Further studies are warranted to elucidate potential roles of FGF23 and α-Klotho in VC and to determine where and how they are synthesized in normal and disease conditions. A thorough systemic evaluation of the biomedical interplay of phosphate, FGF23, and α-Klotho may potentially lead to new therapeutic options for patients with CKD-MBD.

Citing Articles

Risk factors for developing osteoporosis in diabetic kidney disease and its correlation with calcium-phosphorus metabolism, FGF23, and Klotho.

Yang F, Wu Y, Zhang W World J Diabetes. 2025; 16(1):98714.

PMID: 39817221 PMC: 11718466. DOI: 10.4239/wjd.v16.i1.98714.

Risk factors for radial artery calcification in patients with and without uremia.

Hao J, Wang S, Chen T, Yuan B, Hao L BMC Nephrol. 2025; 26(1):18.

PMID: 39799338 PMC: 11724451. DOI: 10.1186/s12882-024-03940-0.

Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.

Siracusa C, Carabetta N, Morano M, Manica M, Strangio A, Sabatino J Int J Mol Sci. 2024; 25(23).

PMID: 39684805 PMC: 11642360. DOI: 10.3390/ijms252313096.

Pedal Vessel Calcification and Risk of Major Adverse Foot Events in the Diabetic Neuropathic, Nephropathic Foot.

Jones M, Bullock G, Crowfoot M, Sinacore D J Am Podiatr Med Assoc. 2024; 114(5).

PMID: 39378173 PMC: 11629881. DOI: 10.7547/23-233.

The role of Klotho and sirtuins in sleep-related cardiovascular diseases: a review study.

Rostamzadeh F, Joukar S, Yeganeh-Hajahmadi M NPJ Aging. 2024; 10(1):43.

PMID: 39358364 PMC: 11447243. DOI: 10.1038/s41514-024-00165-1.

References

Scialla J, Wolf M . Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014; 10(5):268-78. DOI: 10.1038/nrneph.2014.49. View

Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View

McCabe K, Booth S, Fu X, Shobeiri N, Pang J, Adams M . Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013; 83(5):835-44. DOI: 10.1038/ki.2012.477. View

Lau W, Linnes M, Chu E, Foster B, Bartley B, Somerman M . High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol Dial Transplant. 2012; 28(1):62-9. PMC: 3539425. DOI: 10.1093/ndt/gfs333. View

Olauson H, Vervloet M, Cozzolino M, Massy Z, Urena Torres P, Larsson T . New insights into the FGF23-Klotho axis. Semin Nephrol. 2014; 34(6):586-97. DOI: 10.1016/j.semnephrol.2014.09.005. View

Shigematsu T, Kono T, Satoh K, Yokoyama K, Yoshida T, Hosoya T . Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant. 2003; 18 Suppl 3:iii86-9. DOI: 10.1093/ndt/gfg1022. View

Vervloet M, Massy Z, Brandenburg V, Mazzaferro S, Cozzolino M, Urena-Torres P . Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014; 2(5):427-36. DOI: 10.1016/S2213-8587(14)70059-2. View

Jono S, McKee M, Murry C, Shioi A, Nishizawa Y, Mori K . Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. DOI: 10.1161/01.res.87.7.e10. View

Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register T . CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014; 25(8):1760-73. PMC: 4116062. DOI: 10.1681/ASN.2013080818. View

10.

Finch J, Lee D, Liapis H, Ritter C, Zhang S, Suarez E . Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int. 2013; 84(6):1145-53. PMC: 6589836. DOI: 10.1038/ki.2013.213. View

11.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

12.

Shanahan C, Crouthamel M, Kapustin A, Giachelli C . Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109(6):697-711. PMC: 3249146. DOI: 10.1161/CIRCRESAHA.110.234914. View

13.

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

14.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

15.

Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimaki T, Kilpinen S . Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. J Heart Valve Dis. 2009; 18(4):429-38. View

16.

Lewin E, Olgaard K . The vascular secret of Klotho. Kidney Int. 2015; 87(6):1089-91. DOI: 10.1038/ki.2015.80. View

17.

Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D . Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004; 110(22):3424-9. DOI: 10.1161/01.CIR.0000148131.41425.E9. View

18.

Fox C, Larson M, Vasan R, Guo C, Parise H, Levy D . Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol. 2005; 17(2):521-7. DOI: 10.1681/ASN.2005060627. View

19.

Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M . Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol. 2009; 297(5):H1673-84. DOI: 10.1152/ajpheart.00455.2009. View

20.

Paloian N, Giachelli C . A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol. 2014; 307(8):F891-900. PMC: 4200295. DOI: 10.1152/ajprenal.00163.2014. View